Protocol Ledger

NCT06022939 · Phase III · RECRUITING

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

Interventional Phase III clinical trial protocol NCT06022939 sponsored by SWOG Cancer Research Network in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-01 Enrollment: 338 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06022939
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)338 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06022939
Protocol FieldVerified Registry Value
NCT IdentifierNCT06022939
Consolidated Lead SponsorSWOG Cancer Research Network
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment338 participants (ESTIMATED)
Registered Start Date2024-07-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI